信迪利單抗聯(lián)合呋喹替尼治療MSS晚期結(jié)腸癌患者的效果
打開文本圖片集
【關(guān)鍵詞】信迪利單抗呋喹替尼晚期結(jié)腸癌微衛(wèi)星穩(wěn)定型 血管新生
[Abstract] Objective：To investigate the application efect of Sintilimab combined with Fruquintinib in microsatellte stable （MSS）advanced colon cancer.Method： Acording to the random number table method，100 patients with MSS advanced colon cancer admitted to the First Afiliated Hospital of Bengbu Medical University from October 2021 to October 2023 were divided into a control group （ n =50） receiving Fruquintinib treatment and an observation group （n=50）receiving Fruquintinib combined with Sintilimab treatment.The clinical efficacy，immune function，angiogenesis index，adverse reactions and l-year survival rate of the two groups were compared. Result： The total effctive rate of treatment in the observation group was higher than that in the control group （ P <0.05）. Aftertreatment，levelsofhelperTcells，IgA，IgGdecreased inboth groupscomparedtobeforethe treatment，but the observation group showed higher levels than the control group，the diferences were statistically significant （ P <0.05），vascular endothelial growth factor and transforming growth factor- β1 decreased in both groups compared to before the treatment，and theobservation group showed lower levels than the control group，the diferences were statistically significant （ P <0.05）. The incidence of adverse reactions between the two groups were not significantly different （ P >0.05）. The 1-year survival rate of the observation group was 90.00% （45/50），which was higher than （204號 62.00% （31/50）of the control group （ χ2 =10.746， P 0.001）. Conclusion： Compared with Fruquintinib monotherapy， thecombinationof Sintilimab and Fruquintinib can significantly improve clinical efficacy in patients with MSS advanced colorectal cancer，and can reduce the impact on immune function，efectively reduce tumor angiogenesis， and improve the 1-year survival rate， with certain safety.
[Keywords] SintilimabFruquintinib Advanced colorectal carcinomaMicrosatelite stableAngiogenesis First-author'saddress：Departmentof Gastrointestinal Surgery，theFirst Affiliated Hospital of BengbuMedicalUniversity，Bengbu233oo4，China doi：10.3969/j.issn.1674-4985.2025.23.011
結(jié)腸癌是起源于結(jié)腸黏膜上皮的消化道常見惡性腫瘤，全球新發(fā)病例約193萬例，死亡高達(dá)93萬例，其病死率位居惡性腫瘤第二位[。（剩余6900字）